This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
by Zacks Equity Research
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate
Glaxo Files for Label Expansion of Influenza Vaccine in US
by Kinjel Shah
GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
by Zacks Equity Research
Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction
by Zacks Equity Research
Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.
The Zacks Analyst Blog Highlights: Caterpillar, Apple and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caterpillar, Apple and Pfizer
Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents
Caterpillar Stock Slides After Report Accuses It of Tax Fraud
by Madeleine Johnson
On Wednesday, shares of manufacturing giant Caterpillar Inc. (CAT) are sliding, down about 1.5% in late-morning trading after a new report, commissioned by the government, accused the company of tax and accounting fraud, according to The New York Times.
Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA
by Zacks Equity Research
Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
by Sweta Killa
President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day
Stock Market Roundup, March 7: SNAP Falls Again, Drug Stocks Dip
by Ryan McQueeney
Stocks opened in the red and were down slightly throughout the day on Tuesday. The healthcare sector witnessed some volatility after the release of the Republican plan to replace Obamacare and shares of Snap Inc. fell another 11% just days after its highly-anticipated IPO.
Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices
by Parth Panchal
A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.
Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
Trump Tweets, Drug Stocks Tank
by Mark Vickery
???Pricing for the American people will come way down!??? That???s not the only thing: shares of Pfizer (PFE) and Novartis (NOV) fell immediately.
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.
by Zacks Equity Research
Dow 30 Stock Roundup: Wal-Mart, Home Depot Beat on Earnings, Boeing Wins $1.32B Order from Juneyao
by Swarup Gupta
The Dow notched up a record streak of gains over a holiday shortened week.
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
by Arpita Dutt
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.
Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) reported fourth-quarter 2016 loss of $1.83 per share, wider than the Zacks Consensus Estimate of a loss of $1.65.
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
by Zacks Equity Research
Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.
Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy.
The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter
Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%
by Parth Panchal
Pharmaceutical giant Allergan (AGN) announced on Monday they will acquire ZELTIQ Aesthetics (ZLTQ) in a $2.47 billion deal.
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
by Zacks Equity Research
The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.